Insulet (NASDAQ:PODD) Stock Rating Lowered by Wall Street Zen

Insulet (NASDAQ:PODD) was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued on Saturday, Wall Street Zen reports.

PODD has been the topic of several other reports. Citigroup increased their target price on Insulet from $165.00 to $172.00 and gave the company a “neutral” rating in a research note on Wednesday, July 8th. Truist Financial reaffirmed a “hold” rating and set a $153.00 price objective (down from $210.00) on shares of Insulet in a research report on Wednesday, August 5th. Evercore set a $180.00 price objective on Insulet in a report on Monday, July 6th. Stifel Nicolaus lowered their price objective on shares of Insulet from $225.00 to $180.00 and set a “buy” rating on the stock in a research report on Thursday, August 6th. Finally, Oppenheimer downgraded Insulet from an “outperform” rating to a “market perform” rating in a report on Wednesday, August 5th. Thirteen analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $186.68.

Insulet Price Performance

PODD stock opened at $149.01 on Friday. Insulet has a twelve month low of $126.40 and a twelve month high of $354.88. The company has a quick ratio of 1.83, a current ratio of 2.48 and a debt-to-equity ratio of 0.65. The business has a 50 day moving average of $140.58 and a 200 day moving average of $154.31. The firm has a market cap of $10.33 billion, a PE ratio of 27.85, a price-to-earnings-growth ratio of 1.17 and a beta of 1.11.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share for the quarter, beating the consensus estimate of $1.47 by $0.19. The firm had revenue of $801.70 million during the quarter, compared to the consensus estimate of $787.39 million. Insulet had a return on equity of 29.29% and a net margin of 12.29%. The company’s revenue was up 23.5% on a year-over-year basis. During the same period last year, the company earned $1.17 earnings per share. Insulet has set its FY 2026 guidance at 6.460- EPS. On average, research analysts forecast that Insulet will post 6.51 EPS for the current fiscal year.

Hedge Funds Weigh In On Insulet

A number of institutional investors and hedge funds have recently made changes to their positions in the business. State of Wyoming increased its holdings in Insulet by 34.6% in the first quarter. State of Wyoming now owns 284 shares of the medical instruments supplier’s stock valued at $60,000 after buying an additional 73 shares in the last quarter. Optas LLC lifted its position in shares of Insulet by 8.8% in the first quarter. Optas LLC now owns 1,059 shares of the medical instruments supplier’s stock valued at $222,000 after acquiring an additional 86 shares in the last quarter. American Trust lifted its holdings in Insulet by 8.6% in the 1st quarter. American Trust now owns 1,180 shares of the medical instruments supplier’s stock valued at $248,000 after purchasing an additional 93 shares in the last quarter. Basecamp Wealth Advisors LLC lifted its stake in shares of Insulet by 48.3% during the first quarter. Basecamp Wealth Advisors LLC now owns 313 shares of the medical instruments supplier’s stock valued at $66,000 after buying an additional 102 shares during the period. Finally, Elevation Wealth Partners LLC increased its stake in Insulet by 115.6% in the third quarter. Elevation Wealth Partners LLC now owns 194 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 104 shares during the last quarter.

About Insulet

Insulet Corporation is a medical device company that develops, manufactures and sells wearable, tubeless insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company’s primary product platform is Omnipod, which includes the disposable, wearable Pod and a handheld controller or compatible smartphone-based application. Omnipod products include the Omnipod DASH system and the Omnipod 5 Automated Insulin Delivery System, which is designed to integrate with compatible continuous glucose monitoring technology to help automate insulin delivery.